Wolfe Research downgraded Ceridian HCM from Peer Perform to Underperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2024 | $75.00 | Buy | Stifel |
| 11/7/2023 | $87.00 | Buy | UBS |
| 10/23/2023 | $74.00 | Neutral | Goldman |
| 10/5/2023 | $82.00 | Hold → Buy | Needham |
| 7/13/2023 | $69.00 → $71.00 | Outperform → Market Perform | TD Cowen |
| 1/9/2023 | $68.00 | Market Perform | MoffettNathanson |
| 10/31/2022 | $54.00 → $64.00 | Underweight → Equal Weight | Barclays |
| 9/1/2022 | $73.00 | Buy | Citigroup |
Stifel initiated coverage of Ceridian HCM with a rating of Buy and set a new price target of $75.00
UBS initiated coverage of Ceridian HCM with a rating of Buy and set a new price target of $87.00
Goldman initiated coverage of Ceridian HCM with a rating of Neutral and set a new price target of $74.00